Novartis’ Rhapsido EC Approval: A Positive Step, but Not a Thesis Changer

What happened

The European Commission approved Novartis’ Rhapsido (remibrutinib) as the first oral targeted treatment for chronic spontaneous urticaria (CSU) in adults with inadequate response to antihistamines, offering a convenient twice-daily pill without lab monitoring. While the approval adds a new growth asset in immunology and bolsters the pipeline, it alone does not materially offset the looming Entresto loss-of-exclusivity and other headwinds that the DeepValue report identifies as key risks. The report rates Novartis a Potential Sell at ~$144, with a narrow margin of safety and limited upside, given that the stock already prices in strong offset of LOE from priority brands like Kisqali and Kesimpta. Rhapsido’s contribution to near-term sales is likely modest relative to the size of the portfolio, and the approval does not alter the report’s base-case scenario of steady offset rather than acceleration. Thus, while positive for the pipeline narrative, the news does not change the risk-reward calculus from the current cautious stance.

Implication

Over a 6-18 month horizon, the Rhapsido approval supports the view that Novartis can replenish its portfolio, but it does not address the core bear case of Entresto erosion and potential margin compression from M&A integration. Investors should watch for sales traction and any guidance updates, but the existing valuation premium and crowded sentiment suggest limited upside without a broader re-rating catalyst.

Thesis delta

The Rhapsido approval is incrementally positive but does not shift the thesis. The core concerns remain: Entresto LOE, margin dilution from deals, and a premium valuation. The new drug is a building block for the immunology franchise but not a company-transforming event.